IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%

• H.C. Wainwright & Co. said the weaker revenue was likely due to seasonal factors rather than weakness in the company’s broader outlook.
• The brokerage also cited higher-than-expected research and development expenses as a potential factor for the stock’s slump.
• The firm’s target price of $10 represents a potential upside of over 730%.

Shares of Invivyd, Inc (IVVD) plummeted more than 19% to their lowest level in over seven months after a disappointing first-quarter revenue miss rattled investor sentiment. 

Revenue for the first quarter (Q1) came in at $13.7 million, and though it represented a 22% growth from last year, it fell sharply below Wall Street’s estimates of around $18 million, according to Fiscal.ai data. Invivyd reported a loss of $0.13 per share, compared to consensus estimates of a loss of $0.07 per share.

Despite the subdued earnings report, one analyst views the steep selloff in the stock as “overdone.”

H.C. Wainwright Reiterates $10 Price Target For IVVD

H.C. Wainwright & Co. noted that the weaker revenue was likely due to seasonal factors and timing issues rather than weakness in the company’s broader outlook. The brokerage also cited higher-than-expected research and development expense of $30.7 million as a potential factor for the stock’s slump.

The brokerage believes the higher expenses reflect “pivotal spend” ahead of the key VYD2311 readout expected in the third quarter. VYD2311 is Invivyd’s novel antibody being tested as a preventive and treatment option for COVID-19.

The potential biologics license application (BLA) for VYD2311 is seen as the most important value driver of the stock, H.C. Wainwright added, while reiterating a ‘Buy’ rating and a $10 price target. This represents a potential upside of more than 730% from the stock’s current level.

In December 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VYD2311. The designation is intended to accelerate the development and review of treatments for serious conditions and could shorten regulatory review and submission timelines.

Retail Fears IVVD Could Fall Below $1

Retail sentiment for IVVD on Stocktwits remained in the ‘neutral’ territory, amid ‘high’ message volumes.

One investor said they are hoping for a strong Phase 3 update, and noted that without positive trial results, Invivyd could become a sub-$1 stock.

The stock has shed more than 55% of its value so far this year.

Read also: F Stock Headed Toward Best Week In Nearly 6 Years On Energy Storage Momentum – Analyst Believes Execution And Scaling Remain Key

For updates and corrections, email newsroom[at]stocktwits[dot]com.